| pubmed-article:16444269 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16444269 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:16444269 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:16444269 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:16444269 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:16444269 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:16444269 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16444269 | pubmed:dateCreated | 2006-2-8 | lld:pubmed |
| pubmed-article:16444269 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:abstractText | Cancer cells differ from normal cells in their response to chemotherapy. We exploited this dissimilarity by identifying and targeting tumor-specific, cell-surface proteins whose expression is induced by the chemotherapeutic irinotecan (CPT-11; Camptosar). A cytotoxin-armed antibody reactive with one of these drug-induced surface proteins, the LY6D/E48 antigen, originally identified as the target of a monoclonal antibody reactive with squamous cell carcinomas, caused complete regression of colorectal tumor xenografts in mice treated with CPT-11, whereas either agent alone was less effective. These results suggest that a positive therapeutic index may be generated for other drug combinations by immunotherapeutic targeting of chemotherapy-induced antigens. | lld:pubmed |
| pubmed-article:16444269 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16444269 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16444269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16444269 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16444269 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:16444269 | pubmed:issn | 1087-0156 | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:PolakisPaulP | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:RubinfeldBonn... | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:FongSharon... | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:SmithVictoria... | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:RossSarajaneS | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:KoeppenHartmu... | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:UpadhyayArcha... | lld:pubmed |
| pubmed-article:16444269 | pubmed:author | pubmed-author:ClarkSuzanna... | lld:pubmed |
| pubmed-article:16444269 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16444269 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:16444269 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16444269 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16444269 | pubmed:pagination | 205-9 | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:meshHeading | pubmed-meshheading:16444269... | lld:pubmed |
| pubmed-article:16444269 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16444269 | pubmed:articleTitle | Identification and immunotherapeutic targeting of antigens induced by chemotherapy. | lld:pubmed |
| pubmed-article:16444269 | pubmed:affiliation | Departments of Molecular Oncology, Pathology and Translational Oncology, Genentech, Inc., 1 DNA Way, S. San Francisco, California 94080, USA. | lld:pubmed |
| pubmed-article:16444269 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16444269 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16444269 | lld:pubmed |
